Cannabis Sativa (CBDS) 10-Q 20 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 01, 2023
Cover [Abstract]
Entity Registrant Name	Cannabis Sativa, Inc.
Entity Central Index Key	0001360442
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		72,214,039
Entity File Number	000-53571
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	20-1898270
Entity Address Address Line 1	450 Hillside
Entity Address Address Line 2	Dr. #A224
Entity Address City Or Town	Mesquite
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89027
City Area Code	702
Local Phone Number	762-3123
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 114,912	$ 97,445
Investment in equity securities, at fair value	30,000	379,858
Right of use asset	17,687	0
Total Current Assets	162,599	477,303
Advances to related party	75,054	55,666
Right of use asset	0	38,968
Property and equipment, net	2,504	2,709
Intangible assets, net	45,180	158,943
Goodwill	1,837,202	1,837,202
Total Assets	2,122,539	2,570,791
Current Liabilities
Accounts payable and accrued expenses	69,058	164,411
Operating lease liability, current	17,687	28,736
Accrued interest - related parties	16,524	16,374
Convertible notes payable	164,568	168,500
Notes payable to related parties	163,420	91,700
Total Current Liabilities	431,257	469,721
Long-term liabilities
Operating lease liability, long term	0	10,232
Stock payable	665,595	418,156
Total Liabilities	1,096,852	898,109
Stockholders' Equity:
Preferred stock $0.001 par value; 5,000,000 shares authorized; -0- and 777,654 issued and outstanding, respectively	0	0
Common stock $0.001 par value; 495,000,000 shares authorized; 59,827,210 and 45,566,363 shares issued and outstanding, respectively	59,828	45,567
Additional paid-in capital	81,273,471	80,939,618
Accumulated deficit	(81,686,225)	(80,603,069)
Total Cannabis Sativa, Inc. Stockholders' Equity (Deficit)	(352,926)	382,116
Non-Controlling Interest	1,378,613	1,290,566
Total Stockholders' Equity	1,025,687	1,672,682
Total Liabilities and Stockholders' Equity	$ 2,122,539	$ 2,570,791

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	777,654
Preferred Stock, Shares Outstanding	0	777,654
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	495,000,000	495,000,000
Common Stock, Shares, Issued	59,827,210	45,566,363
Common Stock, Shares, Outstanding	59,827,210	45,566,363

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED
Revenues	$ 271,207	$ 383,079	$ 939,772	$ 1,262,868
Cost of Revenues	102,472	149,943	328,481	479,173
Gross Profit	168,735	233,136	611,291	783,695
Operating Expenses
Professional fees	61,065	208,515	222,963	419,923
Depreciation and amortization	37,989	39,440	113,968	124,147
Wages and salaries	143,935	188,622	468,728	559,533
Advertising	1,637	1,599	9,113	33,128
General and administrative	145,633	177,658	435,221	534,022
Total Operating Expenses	390,259	615,834	1,249,993	1,670,753
Loss from Operations	(221,524)	(382,698)	(638,702)	(887,058)
Other (Income) and Expenses
Unrealized (gain) loss on investment	(28,800)	(300,295)	185,083	(404,937)
Employee Retention Credit	(139,970)	0	(139,970)	0
Loss on debt settlement	88,591	0	99,118	0
Loss on sale of investment securities	0	0	155,735	0
Interest expense	37,327	4,228	56,441	23,399
Total Other (Income) Expenses, Net	(42,852)	(296,067)	356,407	(381,538)
Loss Before Income Taxes	(178,672)	(86,631)	(995,109)	(505,520)
Income Taxes	0	0	0	0
Net Loss for the Period	(178,672)	(86,631)	(995,109)	(505,520)
Income (loss) attributable to non-controlling interest - PrestoCorp	49,076	(19,073)	88,047	3,494
Net Loss for the Period Attributable To Cannabis Sativa, Inc.	$ (227,748)	$ (67,558)	$ (1,083,156)	$ (509,014)
Net Loss for the Period per Common Share: Basic & Diluted	$ 0	$ 0	$ (0.02)	$ (0.01)
Basic & Diluted	52,119,640	44,797,896	48,676,647	35,674,130

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Non Controlling Interest Prestocorp
Balance, shares at Dec. 31, 2021		30,746,865	777,654
Balance, amount at Dec. 31, 2021	$ 1,044,900	$ 30,748	$ 778	$ 79,151,240	$ (79,475,968)	$ 1,338,102
Net loss for period	(100,353)	$ 0	$ 0	0	(90,891)	(9,462)
Balance, shares at Mar. 31, 2022		30,746,865	777,654
Balance, amount at Mar. 31, 2022	944,547	$ 30,748	$ 778	79,151,240	(79,566,859)	1,328,640
Balance, shares at Dec. 31, 2021		30,746,865	777,654
Balance, amount at Dec. 31, 2021	1,044,900	$ 30,748	$ 778	79,151,240	(79,475,968)	1,338,102
Net loss for period	(505,520)
Balance, shares at Sep. 30, 2022		44,870,655	695,708
Balance, amount at Sep. 30, 2022	2,307,738	$ 44,871	$ 696	80,905,557	(79,984,982)	1,341,596
Balance, shares at Mar. 31, 2022		30,746,865	777,654
Balance, amount at Mar. 31, 2022	944,547	$ 30,748	$ 778	79,151,240	(79,566,859)	1,328,640
Net loss for period	(318,536)	$ 0	$ 0	0	(350,565)	32,029
Conversion of preferred to common (1:1), shares		131,880	(131,880)
Conversion of preferred to common (1:1), amount	0	$ 132	$ (132)	0	0	0
Conversion of preferred to common (19:1), shares		5,476,237	(288,223)
Conversion of preferred to common (19:1), amount	0	$ 5,476	$ (288)	(5,188)	0	0
Shares issued for services, shares		1,306,242	458,333
Shares issued for services, amount	350,507	$ 1,306	$ 458	348,743	0	0
Shares issued in consideration of notes and interest payable - related parties, shares		7,089,255
Shares issued in consideration of notes and interest payable - related parties, amount	1,417,851	$ 7,089	$ 0	1,410,762	0	0
Balance, shares at Jun. 30, 2022		44,750,479	815,884
Balance, amount at Jun. 30, 2022	2,394,369	$ 44,751	$ 816	80,905,557	(79,917,424)	1,360,669
Net loss for period	(86,631)	$ 0	$ 0	0	(67,558)	(19,073)
Conversion of preferred to common (1:1), shares		120,176	(120,176)
Conversion of preferred to common (1:1), amount	0	$ 120	$ (120)	0	0	0
Balance, shares at Sep. 30, 2022		44,870,655	695,708
Balance, amount at Sep. 30, 2022	2,307,738	$ 44,871	$ 696	80,905,557	(79,984,982)	1,341,596
Balance, shares at Dec. 31, 2022		45,566,363
Balance, amount at Dec. 31, 2022	1,672,682	$ 45,567	0	80,939,618	(80,603,069)	1,290,566
Net loss for period	(500,101)	$ 0	0	0	(522,922)	22,821
Common Stock Issued - Note Payable Conversion, shares		320,513
Common Stock Issued - Note Payable Conversion, amount	25,637	$ 321	0	25,316	0	0
Balance, shares at Mar. 31, 2023		45,886,876
Balance, amount at Mar. 31, 2023	1,198,218	$ 45,888	0	80,964,934	(81,125,991)	1,313,387
Balance, shares at Dec. 31, 2022		45,566,363
Balance, amount at Dec. 31, 2022	1,672,682	$ 45,567	0	80,939,618	(80,603,069)	1,290,566
Net loss for period	(995,109)
Balance, shares at Sep. 30, 2023		59,827,210
Balance, amount at Sep. 30, 2023	1,025,687	$ 59,828	0	81,273,471	(81,686,225)	1,378,613
Balance, shares at Mar. 31, 2023		45,886,876
Balance, amount at Mar. 31, 2023	1,198,218	$ 45,888	0	80,964,934	(81,125,991)	1,313,387
Net loss for period	(316,336)	$ 0	0	0	(332,486)	16,150
Shares issued for services, shares		2,450,000
Shares issued for services, amount	88,200	$ 2,450	0	85,750	0	0
Common Stock Issued - Note Payable Conversion, shares		1,711,397
Common Stock Issued - Note Payable Conversion, amount	39,000	$ 1,711	0	37,289	0	0
Balance, shares at Jun. 30, 2023		50,048,273
Balance, amount at Jun. 30, 2023	1,009,082	$ 50,049	0	81,087,973	(81,458,477)	1,329,537
Net loss for period	(178,672)	$ 0	0	0	(227,748)	49,076
Common Stock Issued - Note Payable Conversion, shares		9,778,937
Common Stock Issued - Note Payable Conversion, amount	195,277	$ 9,779	0	185,498	0	0
Balance, shares at Sep. 30, 2023		59,827,210
Balance, amount at Sep. 30, 2023	$ 1,025,687	$ 59,828	$ 0	$ 81,273,471	$ (81,686,225)	$ 1,378,613

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (995,109)	$ (505,520)
Adjustments to reconcile net loss for the period to net cash used in operating activities:
Unrealized loss (gain) on investments	185,083	(404,937)
Interest Expense - Default on Notes	21,223	0
Depreciation and amortization	113,968	124,147
Loss on debt settlement	99,231	0
Loss on sale of investment securities	155,735	0
Stock issued for services	88,200	350,507
Stock payable for services	319,701	206,946
Note payable issued for services	70,000	45,000
Write off of abandoned equipment	0	583
Changes in Assets and Liabilities:
Accounts payable and accrued expenses	(90,142)	47,020
Accrued interest - related parties	150	15,524
Net Cash Used in Operating Activities	(31,960)	(120,730)
Cash Flows from Investing Activities:
Cash purchase of equipment	0	(1,590)
Proceeds from sale of stock held for investment	9,040	0
Advances to related party	(19,388)	0
Net Cash Used in Investing Activities	(10,348)	(1,590)
Cash Flows from Financing Activities:
Proceeds from related parties notes payable, net	26,719	38,540
Proceeds from convertible note payable	33,056	104,250
Net Cash Provided by Financing Activities	59,775	142,790
NET CHANGE IN CASH	17,467	20,470
CASH AT BEGINNING OF PERIOD	97,445	194,060
CASH AT END OF PERIOD	114,912	214,530
Noncash investing and financing activities
Shares issued in consideration of notes and interest payable - related parties	30,000	1,417,851
Recognition of operating lease liability and right of use asset	0	56,595
Shares issued in consideration of convertible notes payable	$ 160,236	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Organization and Summary of Significant Accounting Policies
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Nature of Business: Cannabis Sativa, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including: · PrestoCorp, Inc. (“PrestoCorp”) · Wild Earth Naturals, Inc. (“Wild Earth”) · Kubby Patent and Licenses Limited Liability Company (“KPAL”) · Hi Brands, International, Inc. (“Hi Brands”) · Eden Holdings LLC (“Eden”). PrestoCorp is a 51% owned subsidiary and until April 22, 2021, GKMP and iBud were 51% and 50.1% owned subsidiaries. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At December 31, 2022 and 2021, PrestoCorp is the sole operating subsidiary. Until sale of the Company’s interest in April 2021, GKMP and iBud tender were operating subsidiaries although iBud was not generating any revenue. Our primary operations for the years ended December 31, 2022 through September 30, 2023 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries. Basis of Presentation Operating results for the three and nine months ended September 30, 2023 may not be indicative of the results expected for the full year ending December 31, 2023. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2022, as filed with the United States Securities and Exchange Commission on April 20, 2023. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2023, and its results of operations, cash flows, and changes in stockholders’ equity for the three and nine months ended September 30, 2023. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements. Principles of Consolidation: The consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation. Going Concern: The Company has an accumulated deficit of $81,686,225 at September 30, 2023, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due. Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards. Net Loss per Share: Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the nine months ended September 30, 2023 and 2022, the Company had 50,000 and 175,000 outstanding warrants, respectively, and -0- and 777,654 shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted. The number of shares that can be converted per the convertible note agreement can be converted after December 31, 2022 thus are dilutive as of September 30, 2023. Recent Accounting Pronouncement: Accounting Standards Updates Adopted In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Intangibles and Goodwill

Intangibles and Goodwill	9 Months Ended
	Sep. 30, 2023
Intangibles and Goodwill
Intangibles and Goodwill	2. Intangibles and Goodwill The Company considers all intangibles to be definite-lived assets with lives of 5 to 10 years. Intangibles consisted of the following at September 30, 2023 and December 31, 2022: September 30, 2023 December 31, 2022 CBDS.com website (Cannabis Sativa) $ 13,999 $ 13,999 Intellectual Property Rights (PrestoCorp) 240,000 240,000 Patents and Trademarks (KPAL) 1,281,411 1,281,411 Total Intangibles 1,535,410 1,535,410 Less: Accumulated Amortization (1,490,230 ) (1,376,467 ) Net Intangible Assets $ 45,180 $ 158,943 Amortization expense for the three and nine months ended September 30, 2023 and 2022 was $37,921 (2022: $39,372) and $113,763 (2022: $123,942), respectively. Amortization of intangibles through 2029 is: October 1, 2023 to September 30, 2024 $ 40,744 October 1, 2024 to September 30, 2025 932 October 1, 2025 to September 30, 2026 932 October 1, 2026 to September 30, 2027 932 October 1, 2027 to September 30, 2028 932 October 1, 2028 to September 30, 2029 708 Goodwill in the amount of $3,010,202 was recorded as part of the acquisition of PrestoCorp that occurred on August 1, 2017. Cumulative impairment of the PrestoCorp goodwill totals $1,173,000 as of September 30, 2023 and December 31, 2022. The balance of goodwill at September 30, 2023 and December 31, 2022 was $1,837,202.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions
Related Party Transactions	3. Related Party Transactions In addition to items disclosed in Note 6, the Company had additional related party transactions during the nine months ended September 30, 2023 and 2022. Historically, the Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company’s outstanding shares. During the nine months ended September 30, 2023, David Tobias, the Company’s chief executive officer and director, loaned $22,721 to the Company for notes payable bearing interest at the rate of 5% per annum due on December 31, 2023. During the nine months ended September 30, 2023, the Company and Cathy Carroll, director, entered into a note payable for $45,000 for compensation due her for services. Ms. Carroll’s note bears interest at 8% per annum and is due December 31, 2024. The note payable totaled $100,000 and $55,000 at September 30, 2023 and December 31, 2022, respectively. During the nine months ended September 30, 2023, the Company recorded interest expense related to notes payable to related parties at the rates between 5% and 8% per annum in the amounts of $16,374 and $66,872, respectively. The following tables reflect the related party note payable balances. Related party notes Accrued interest Total September 30, 2023 David Tobias, CEO & Director $ 59,420 $ 12,482 $ 71,902 New Compendium, greater than 10% Shareholder - 1,906 1,906 Cathy Carroll, Director 100,000 986 100,986 Other Affiliates 4,000 1,150 5,150 Totals $ 163,420 $ 16,524 $ 179,944 Related party notes Accrued interest Total December 31, 2022 David Tobias, CEO & Director $ 32,700 $ 12,482 $ 45,182 New Compendium, greater than 10% Shareholder –– 1,906 1,906 Cathy Carroll, Director 55,000 986 55,986 Other Affiliates 4,000 1,000 5,000 Totals $ 91,700 $ 16,374 $ 108,074 During the three and nine months ended September 30, 2023 and 2022, the Company incurred approximately $-0- (2022: $-0-) and $-0- (2022: $26,389), respectively, for consulting services from a nephew of the Company’s president. The services were accrued at September 30, 2022 and paid in common stock. These amounts are included in the statements of operations in general and administrative expenses. At September 30, 2023 and December 31, 2022, the Company has a balance due from MJ Harvest, Inc., with whom the Company plans to merge, of $75,054 and $55,666 (see Note 8). The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to MJ Harvest, Inc. to cover operating expenses. At September 30, 2023 and December 31, 2022 the Company had stock payable in the amount $521,874 and $345,893 due to related parties; directors and contract officers. Income Statement Nine months ended September 30, 2023 Nine months ended September 30, 2022 Directors' fee $ 35,625 $ 45,000 Outside services 178,125 318,750 Management fee 77,201 141,000 Payroll expenses 37,044 -0-

Investments

Investments	9 Months Ended
	Sep. 30, 2023
Investments
Investments	4. Investments At September 30, 2023 and December 31, 2022, the Company owns -0- and 8,238,769 shares respectively, of common stock of Medical Cannabis Payment Solutions (ticker: REFG). At September 30, 2023 and December 31, 2022, the fair value of the investment in REFG was $-0- and $12,358, respectively. The Company sold all of its position in REFG during the nine months ended September 30, 2023 and recognized a loss on the sale of investment securities in the amount of $155,735. In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG. The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at September 30, 2023 and December 31, 2022 was $30,000 and $367,500 resulting in a gain (loss) of $28,800 (2022: $300,295) and ($337,500) (2022: $404,937) for the change in fair value during the three and nine months ended September 30, 2023 and 2022, respectively.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2023
Convertible Notes Payable
Convertible Notes Payable	5. Convertible Notes Payable On August 25, 2022 and November 7, 2022, the Company entered into an agreement with 1800 Diagonal Lending, LLC (“Diagonal”) whereby the Company issued convertible notes to Diagonal with principal amounts of $104,250 and $64,250, respectively. The notes bear interest at 10% and have terms of one year when payment of principal and interest is due. After 180 days, the notes are convertible into shares of the Company’s common stock the number of which determined by dividing the principal balance outstanding by 65% of the lowest trading price of the Company’s stock during the five previous trading days before the date of the conversion. During the nine months ended September 30, 2023, Diagonal converted $134,250 of their notes payable plus $26,435 of default proceeds and interest into 11,810,847 shares of common stock. As of September 30, 2023 amount due to Diagonal is $34,250. On January 1, 2023, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $72,262. As stated in the January 1, 2023 agreement Ms Merrill’s contract compensation will also be added to the note for her services through September 30, 2023 in the amount of $25,000. Total note payable at September 30, 2023 is $97,262. The note bears interest at 8% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 20% discount. Both methods are calculated using the lowest 3 closing prices during the 15 trading days preceding the first day of the next calendar quarter. On September 18, 2023 the Company entered into an agreement with Quick Capital, LLC whereby the Company issued a convertible note with a principal amount of $33,055. The maturity date is nine months after the issue date, accruing interest at 12% per annum and can be converted after 180 days from date of issue at a fixed rate of $0.01 per share. At September 30, 2023 and December 31, 2022, accrued interest payable and interest expense on these notes was $14,433 and $4,546. Accrued interest payable is included in accounts payable and accrued expenses on the consolidated balance sheet.

Stockholders Equity

Stockholders Equity	9 Months Ended
	Sep. 30, 2023
Stockholders Equity
Stockholders' Equity	6. Stockholders’ Equity Change in Authorized Shares The Company increased the number of authorized common shares the Company is authorized to issue to 495,000,000 on August 8, 2022. This change in capital structure was approved without a meeting by the consent of the shareholders holding a majority of the common stock outstanding and Articles of Amendment were filed with the State of Nevada. Securities Issuances During the nine months ended September 30, 2023, 11,811,847 shares of common stock were issued to convert $160,685 of a notes payable to a non-related party. See Note 5. During the nine months ended September 30, 2023, 2,450,000 shares of common stock were issued to pay bonuses in the amount of $88,200. Stock payable at September 30, 2023 consists of preferred shares and common shares owed to members of the board of directors for directors’ fees and contract services. These shares were valued at $521,874 based on the fair value of the Company’s common stock at the date of board authorization. Stock payable at December 31, 2022 consists preferred shares and common shares, respectively, owed to members of the board of directors for directors’ fees and contract services. These shares were valued at $212,500, based on the fair value of the Company’s common stock at the date of board authorization. Common shares were owed to various non-related vendors at September 30, 2023 and December 31, 2022 valued at $143,721 and $205,656, respectively, based on the fair value of the Company’s common stock at the date of board authorization. Subsequent, to year end, no issuances of the shares have been made. Stock Compensation Plans 2020 Stock Plan On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021. At September 30, 2023, 44,425 shares were available for future issuance. Warrants At September 30, 2023 and December 31, 2022, the Company has outstanding warrants to purchase 50,000 shares of the Company’s common stock. As of September 30, 2023, the warrants have an exercise price of $2.00 and expire in July and August 2023. During the nine months ended September 30, 2023 and 2022, warrants activity consisted of the following: warrants issued – none (2022: none), warrants exercised – none (2022: none), warrants expired – none (2022: none).

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and contingencies (Notes 6 and 8)
Commitments and Contingencies	7. Commitments and Contingencies Leases. PrestoCorp leased office space through WeWork in New York on a month-to-month basis which ended in April 2022. On April 12, 2022, PrestoCorp signed a new lease in New York with Spaces for a two-year term at $2,590 per month expiring in April 2024. Upon signing the lease with Spaces, the Company recognized a lease liability and a right of use asset of $56,595 using a discount rate of 10%. The future lease payments under the new lease are as follows: From October 1, 2023 to September 30, 2024 $ 18,130 Less imputed interest (443 ) Net lease liability 17,687 Current Portion (17,687 ) Long-term portion $ -0- Rent expense for the three and nine months ended September 30, 2023 and 2022 was $9,119 (2022: $-0-) and $26,698 (2022: $21,325), respectively. Litigation. In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of September 30, 2023, no claims are outstanding.

Proposed Merger with MJ Harvest

Proposed Merger with MJ Harvest Inc	9 Months Ended
	Sep. 30, 2023
Proposed Merger with MJ Harvest Inc
Proposed Merger with MJ Harvest, Inc.	8. Proposed Merger with MJ Harvest, Inc. On August 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with MJ Harvest, Inc. (“MJHI”). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger. The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the second quarter of calendar year 2023. The terms of the Merger Agreement are summarized below: · The name of the surviving company in the Merger will be Cannabis Sativa, Inc. · Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock. · The Merger is subject to majority approval of the shareholders of both MJHI and CBDS. · The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares. · The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Randy Lanier, Clinton Pyatt, and David Tobias. · The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer, Clinton Pyatt - Chief Operating Officer. · The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature. · No brokerage fees are payable in connection with the Merger. · If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated. · All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2023
Subsequent Event
Subsequent Event	9. Subsequent Event Subsequent to September 30, 2023 the remaining convertible note of $34,250 was converted in full to 12,386,827 shares of common stock, which included $1,530 of accrued interest.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Organization and Summary of Significant Accounting Policies
Nature of Business	Cannabis Sativa, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including: · PrestoCorp, Inc. (“PrestoCorp”) · Wild Earth Naturals, Inc. (“Wild Earth”) · Kubby Patent and Licenses Limited Liability Company (“KPAL”) · Hi Brands, International, Inc. (“Hi Brands”) · Eden Holdings LLC (“Eden”). PrestoCorp is a 51% owned subsidiary and until April 22, 2021, GKMP and iBud were 51% and 50.1% owned subsidiaries. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At December 31, 2022 and 2021, PrestoCorp is the sole operating subsidiary. Until sale of the Company’s interest in April 2021, GKMP and iBud tender were operating subsidiaries although iBud was not generating any revenue. Our primary operations for the years ended December 31, 2022 through September 30, 2023 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.
Basis of Presentation	Operating results for the three and nine months ended September 30, 2023 may not be indicative of the results expected for the full year ending December 31, 2023. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2022, as filed with the United States Securities and Exchange Commission on April 20, 2023. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2023, and its results of operations, cash flows, and changes in stockholders’ equity for the three and nine months ended September 30, 2023. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.
Principles of Consolidation	The consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.
Going Concern	The Company has an accumulated deficit of $81,686,225 at September 30, 2023, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.
Use of Estimates	The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.
Net Loss per Share	Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the nine months ended September 30, 2023 and 2022, the Company had 50,000 and 175,000 outstanding warrants, respectively, and -0- and 777,654 shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted. The number of shares that can be converted per the convertible note agreement can be converted after December 31, 2022 thus are dilutive as of September 30, 2023.
Recent Accounting Pronouncement	Accounting Standards Updates Adopted In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Intangibles and Goodwill (Table

Intangibles and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2023
Intangibles and Goodwill
Schedule of Intangible Assets	September 30, 2023 December 31, 2022 CBDS.com website (Cannabis Sativa) $ 13,999 $ 13,999 Intellectual Property Rights (PrestoCorp) 240,000 240,000 Patents and Trademarks (KPAL) 1,281,411 1,281,411 Total Intangibles 1,535,410 1,535,410 Less: Accumulated Amortization (1,490,230 ) (1,376,467 ) Net Intangible Assets $ 45,180 $ 158,943
Schedule of amortization	October 1, 2023 to September 30, 2024 $ 40,744 October 1, 2024 to September 30, 2025 932 October 1, 2025 to September 30, 2026 932 October 1, 2026 to September 30, 2027 932 October 1, 2027 to September 30, 2028 932 October 1, 2028 to September 30, 2029 708

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2023
Related Party Transactions
Schedule of related party advance and note payable	Related party notes Accrued interest Total September 30, 2023 David Tobias, CEO & Director $ 59,420 $ 12,482 $ 71,902 New Compendium, greater than 10% Shareholder - 1,906 1,906 Cathy Carroll, Director 100,000 986 100,986 Other Affiliates 4,000 1,150 5,150 Totals $ 163,420 $ 16,524 $ 179,944 Related party notes Accrued interest Total December 31, 2022 David Tobias, CEO & Director $ 32,700 $ 12,482 $ 45,182 New Compendium, greater than 10% Shareholder –– 1,906 1,906 Cathy Carroll, Director 55,000 986 55,986 Other Affiliates 4,000 1,000 5,000 Totals $ 91,700 $ 16,374 $ 108,074
Schedule of Income Statement	Nine months ended September 30, 2023 Nine months ended September 30, 2022 Directors' fee $ 35,625 $ 45,000 Outside services 178,125 318,750 Management fee 77,201 141,000 Payroll expenses 37,044 -0-

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and contingencies (Notes 6 and 8)
Schedule of future lease payments	From October 1, 2023 to September 30, 2024 $ 18,130 Less imputed interest (443 ) Net lease liability 17,687 Current Portion (17,687 ) Long-term portion $ -0-

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Accumulated deficit	$ (81,686,225)		$ (80,603,069)
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	50,000	175,000
Convertible Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	777,654
Cannabis Sativa [Member] | Internet Domain Names [Member]
Equity Method Investment, Ownership Percentage	50.10%
Preferred Stock [Member]
Equity Method Investment, Ownership Percentage	51%

Intangibles and Goodwill (Detai

Intangibles and Goodwill (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Total Intangibles	$ 1,535,410	$ 1,535,410
Less: Accumulated Amortization	(1,490,230)	(1,376,467)
Net Intangible Assets	45,180	158,943
Intellectual Property [Member] | Prestocorp [Member]
Total Intangibles	240,000	240,000
Cannabis Sativa [Member] | Internet Domain Names [Member]
Total Intangibles	13,999	13,999
K P A L [Member] | Patents And Trademarks [Member]
Total Intangibles	$ 1,281,411	$ 1,281,411

Intangibles and Goodwill (Det_2

Intangibles and Goodwill (Details 1)	Sep. 30, 2023 USD ($)
Intangibles and Goodwill
October 1, 2023 to September 30, 2024	$ 40,744
October 1, 2024 to September 30, 2025	932
October 1, 2025 to September 30, 2026	932
October 1, 2026 to September 30, 2027	932
October 1, 2027 to September 30, 2028	932
October 1, 2028 to September 30, 2029	$ 708

Intangibles and Goodwill (Det_3

Intangibles and Goodwill (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Amortization of Intangible Assets	$ 37,921	$ 39,372	$ 113,763	$ 123,942
Goodwill	1,837,202		1,837,202		$ 1,837,202
Prestocorp [Member] | August 1, 2017 [Member]
Impairment of goodwill			3,010,202
Cumulative impairment of goodwill	$ 1,173,000		$ 1,173,000		$ 1,173,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life			5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life			10 years

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Notes Payable to Related Parties	$ 163,420	$ 91,700
Accrued interest - related parties	16,524	16,374
Total	179,944	108,074
New Compendium Affiliate [Member]
Notes Payable to Related Parties	0	0
Accrued interest - related parties	1,906	1,906
Total	1,906	1,906
Other Affiliates [Member]
Notes Payable to Related Parties	4,000	4,000
Accrued interest - related parties	1,150	1,000
Total	5,150	5,000
David Tobias, CEO &amp
Notes Payable to Related Parties	59,420	32,700
Accrued interest - related parties	12,482	12,482
Total	71,902	45,182
Cathy Carroll, Director
Notes Payable to Related Parties	100,000	55,000
Accrued interest - related parties	986	986
Total	$ 100,986	$ 55,986

Related Party Transactions (D_2

Related Party Transactions (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Related Party Transactions
Directors' fee	$ 35,625	$ 45,000
Outside services	178,125	318,750
Management fee	77,201	141,000
Payroll expanses	$ 37,044	$ 0

Related Party Transactions (D_3

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Interest Expense			$ 16,374	$ 66,872
Advances to related party	$ 75,054		$ 75,054		$ 55,666
Interest rate			12%
Cathy Carroll, Director
Compensation due for services			$ 45,000
Interest rate			8%
Note Payable	100,000		$ 100,000		55,000
Directors And Contract Officers [Member]
Stock payable due to related parties			626,796		345,893
David Tobias, Director
Advances to related party	75,054		$ 75,054		55,666
Interest rate			5%
Note Payable	22,721		$ 22,721
Consultant [Member]
Other General and Administrative Expense	0	$ 0	0	$ 26,389
MJ Harvest, Inc.
Due from related parties	75,054		75,054		55,666
Director
Due to related parties	$ 521,874		$ 521,874		$ 345,893
Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	5%		5%
Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	8%		8%

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Stock Issued During Period, Shares, Purchase of Assets			0		8,238,769
Unrealized (gain) loss on investment			$ 155,735
C B D G [Member]
Share price					$ 0.20
Fair value of investment	$ 30,000		30,000		$ 367,500
Proceeds from sales of equity					$ 600,000
Percentage of voting share held by director					15%
Unrealized (gain) loss on investment	(28,800)	$ (300,295)	(337,500)	$ (404,937)
C B D G [Member] | Common Stock One [Member]
Stock Issued During Period, Shares, Purchase of Assets						1,500,000
C B D G [Member] | Preferred Stock One [Member]
Stock Issued During Period, Shares, Purchase of Assets						1,500,000
R E F G [Member]
Fair value of investment	$ 0		$ 0		$ 12,358

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Common Stock, Shares Authorized	495,000,000		495,000,000
Stock payable	521,874
Additional common shares owed to various non-related vendors, Amount	$ 2,450,000		$ 205,656
Stock issued for services	$ 88,200	$ 350,507
Warrants
Outstanding warrants	50,000		50,000
Exercise price			$ 2
2021 Stock Plan
Shares available for future issuance	44,425
2020 Stock Plan
Shares available for future issuance	1,000,000
Increased number of shares available for future issuance	2,000,000
Non Related Party [Member]
Common stock shares issued	11,811,847
Convertible notes payable	$ 160,685
Board of Directors [Member] | Common Stock [Member]
Stock payable	143,721		212,500

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)		9 Months Ended
	Jan. 02, 2023	Sep. 30, 2023	Jan. 01, 2023	Dec. 31, 2022	Nov. 07, 2022	Aug. 25, 2022
Principal Amount		$ 33,055
Interest rate		12%
Common Stock, Par or Stated Value Per Share		$ 0.01
Accrued interest payable and interest expense		$ 14,433		$ 4,546
Diagonal Lending, LLC [Member]
Principal Amount					$ 64,250	$ 104,250
Principal balance outstanding lowest trading price, percentage						65%
Common stock shares issued		11,810,847
Notes payable due		$ 34,250
Convertible notes payable		134,250
Notes Payable		26,435
Carolyn Merrill [Member]
Principal Amount			$ 72,262
Interest rate	8%
Compensation			$ 25,000
Agreement payment description	If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 20% discount
Notes Payable		$ 97,262

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Commitments and contingencies (Notes 6 and 8)
From October 1, 2023 to September 30, 2024	$ 18,130
Less imputed interest	443
Net lease liability	17,687
Current Portion	(17,687)	$ (28,736)
Long-term portion	$ 0	$ 10,232

Commitments and Contingencies_3

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Recognition of operating lease liability and right of use asset			$ 56,595
Discount rate	10%		10%
Prestocorp [Member] | New York office Facilities
Description of lease			two-year term at $2,590 per month expiring in April 2024
Rent expense	$ 9,119	$ 0	$ 26,698	$ 21,325

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	Oct. 01, 2023	Sep. 30, 2023	Dec. 31, 2022
Common stock, shares issued		59,827,210	45,566,363
Accrued interest		$ 14,433	$ 4,546
Subsequent Event
Common stock, shares issued	12,386,827
Convertible notes payable	$ 34,250
Accrued interest	$ 1,530